GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Cyclically Adjusted FCF per Share

Amgen (BSP:AMGN34) Cyclically Adjusted FCF per Share : R$2.93 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Amgen Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amgen's adjusted free cash flow per share for the three months ended in Mar. 2024 was R$0.152. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$2.93 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Amgen's average Cyclically Adjusted FCF Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amgen was 29.40% per year. The lowest was 10.70% per year. And the median was 17.10% per year.

As of today (2024-05-16), Amgen's current stock price is R$58.05. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$2.93. Amgen's Cyclically Adjusted Price-to-FCF of today is 19.81.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 29.70. The lowest was 13.20. And the median was 20.12.


Amgen Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Amgen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted FCF per Share Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 2.26 2.82 3.01 2.88

Amgen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.82 3.03 2.88 2.93

Competitive Comparison of Amgen's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.



Amgen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.152/129.4194*129.4194
=0.152

Current CPI (Mar. 2024) = 129.4194.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.214 100.560 0.275
201409 0.262 100.428 0.338
201412 0.306 99.070 0.400
201503 0.199 99.621 0.259
201506 0.449 100.684 0.577
201509 0.512 100.392 0.660
201512 0.339 99.792 0.440
201603 0.306 100.470 0.394
201606 0.387 101.688 0.493
201609 0.400 101.861 0.508
201612 0.464 101.863 0.590
201703 0.334 102.862 0.420
201706 0.341 103.349 0.427
201709 0.503 104.136 0.625
201712 0.463 104.011 0.576
201803 0.424 105.290 0.521
201806 0.391 106.317 0.476
201809 0.701 106.507 0.852
201812 0.642 105.998 0.784
201903 0.379 107.251 0.457
201906 0.287 108.070 0.344
201909 0.784 108.329 0.937
201912 0.571 108.420 0.682
202003 0.585 108.902 0.695
202006 0.840 108.767 0.999
202009 1.059 109.815 1.248
202012 0.623 109.897 0.734
202103 0.671 111.754 0.777
202106 0.544 114.631 0.614
202109 0.720 115.734 0.805
202112 0.903 117.630 0.994
202203 0.637 121.301 0.680
202206 0.565 125.017 0.585
202209 0.981 125.227 1.014
202212 0.804 125.222 0.831
202303 0.249 127.348 0.253
202306 1.239 128.729 1.246
202309 0.824 129.860 0.821
202312 0.094 129.419 0.094
202403 0.152 129.419 0.152

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Amgen  (BSP:AMGN34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amgen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=58.05/2.93
=19.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 29.70. The lowest was 13.20. And the median was 20.12.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amgen Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (BSP:AMGN34) Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BSP:AMGN34) Headlines

No Headlines